Sponsored Content by QuanterixReviewed by Olivia FrostJun 4 2024
Quanterix’s assays, complemented by the expertise of its Accelerator Lab, empower researchers to extend the frontiers of Alzheimer’s disease research.
By utilizing Quanterix, researchers unlock the potential for groundbreaking discoveries and contribute to the ongoing battle against neurodegenerative diseases with unparalleled precision and confidence. Opting for Quanterix means joining a collaborative effort to redefine Alzheimer’s research, ultimately paving the way for a brighter future.
Convenient assay kit option
The Simoa® ALZpath p-Tau 217 Advantage PLUS assay kit (104570) is designed for seamless implementation and precise p-Tau 217 quantification on the HD-X™. The user-friendly protocols allow researchers of all levels to set up an easy and simplified assay in their labs.
Robust and quantitative p-Tau 217 measurements provide comprehensive data to drive impactful research outcomes.
Pricing for p-Tau 217 research
The Quanterix team is committed to providing the most relevant and tailored pricing options to meet your specific needs. Detailed pricing information regarding the ALZpath p-Tau 217 Advantage PLUS assay is available from a dedicated Quanterix representative.
Source: Quanterix
| . |
. |
| Assay Platform |
Quanterix Simoa® |
| Instrument |
HD-X Analyzer |
| General Description |
2-step digital enzyme immunoassay |
| Automation |
Fully automated |
| Assay Timing |
60-5 min |
| Capture Antibody |
Rabbit monoclonal IgG: p-Tau 217 |
| Detector Antibody |
Mouse monoclonal IgG1 to the N-terminus of tau (441) |
| Calibrator Material |
Synthetic peptide |
| Dynamic Range |
0.007-30.0 pg/mL |
| Calibrator Points # |
7 + blank |
| Calibrator Fitting |
1/y^2 weighted 5PL |
| Signal Enzyme/Substrate |
Streptavidin-b-galactosidase (SBG) |
| Substrate |
Resorufin-β-D-galacto pyranoside |
| Sample Type |
Human plasma (EDTA) |
| Sample Volume |
100 μL for duplicate testing (on-board) |
| Sample Dilution |
3x |
| Limit of Detection |
0.021pg/mL1 (corrected for dilution) |
| Limit of Quantification |
0.060 pg/mL1 (corrected for dilution) |
| Intra-Run Precision (%CV) |
2.8-6.8% (plasma, 2 runs, 40 reps)1 |
| Inter-Run Precision (%CV) |
14.9-20.3% (3 plasma spms, 20 days)1 |
| Parallelism |
Up to 8-fold dilution1 |
| Clinical Accuracy CI A+T+ |
AUC 0.912,3,4 |
| Clinical accuracy CU Ab |
AUC 0.842,3,4 |
Citations
1. QTRX fit-for-purpose validation report
2. Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurol. Published online January 22, 2024. doi:10.1001/jamaneurol.2023.5319
3. Brum WS, Ashton NJ, Simrén J, et al. Biological variation estimates of Alzheimer‘s disease plasma biomarkers in healthy individuals. Alzheimers Dement. Published online November 20, 2023. doi:10.1002/alz.13518
4. Xiao Z, Wu W, Ma X, et al. Plasma p-tau217, p-tau181, and NfL as early indicators of dementia risk in a community cohort: The Shanghai Aging Study. Alzheimers Dement (Amst). 2023;15(4):e12514. Published 2023 Dec 22. doi:10.1002/dad2.12514
About Quanterix 
From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. Quanterix’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods.
Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,500 peer-reviewed journals.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.